eligibility_summary
Eligible: Age 3–70, r/r T‑ALL/LBL/AML with CD7+ and ≥5% marrow blasts, adequate renal/hepatic function, LVEF ≥50%, O2 sat ≥92%, ECOG 0–2, survival >3 mo, consent. Exclude: marrow‑failure syndromes, isolated extramedullary disease, significant cardiac disease, uncontrolled CNS leukemia, neuro history impairing compliance, other malignancy, primary immunodeficiency, uncontrolled infection or HIV/HBV/HCV/syphilis, recent anticancer therapy or systemic steroids, live vaccine <4 wks, allergy, pregnancy/breastfeeding, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: RD13-02 cell infusion—an autologous CD7-directed chimeric antigen receptor T-cell (CAR-T) therapy (cellular gene therapy). Mechanism of action: Patient T cells are engineered to express a CAR that binds CD7, antigen engagement activates CAR signaling (CD3ζ with costimulation), driving T-cell activation, proliferation, and cytotoxic killing (perforin/granzyme, cytokines) of CD7-expressing cells, in vivo expansion/persistence are assessed. Targets: CD7 on malignant cells in r/r T-ALL, lymphoblastic lymphoma, and CD7-positive AML, engages T-cell activation pathways to eliminate CD7+ hematologic blasts.